Evidence map›Paper›PMID 42293855›Full record

ArticleTranslational andrology and urology2026

NOX4 suppresses malignant progression in prostate adenocarcinoma and functions as a potential diagnostic biomarker.

Jimeng Hu, Min Zhou, Xiaobo Wu, Mengbo Hu

Abstract read
In one paragraph

Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jimeng Hu *Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Min Zhou *Department of Nursing, Huashan Hospital, Fudan University, Shanghai, China.
Xiaobo WuDepartment of Surgery (Urology), Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Mengbo HuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate adenocarcinoma (PRAD) is a highly prevalent malignant tumor in males and exhibits substantial heterogeneity. Identifying key associated genes is therefore critical for improving disease diagnosis and therapeutic strategies. Methods: In this study, we first analyzed gene expression profiles to identify differentially expressed genes (DEGs) between PRAD and normal tissues. Subsequently, a weighted gene co-expression network analysis (WGCNA) was performed to elucidate the functional roles and signaling pathways of key genes, supported by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) enrichment analyses. To prioritize robust diagnostic markers, three machine learning algorithms, least absolute shrinkage and selection operator (LASSO) regression, support vector machine with recursive feature elimination (SVM-RFE), and random forest, were integrated, and their intersection yielded six core genes: Results: Results from the DCFH-DA fluorescence assay showed that NOX4 overexpression significantly elevated intracellular reactive oxygen species (ROS) levels and activated the PI3K/AKT/ERK signaling pathway in PRAD cells. Conclusions: These findings suggest that NOX4 may regulate the redox balance of PRAD cells while activating the PI3K/AKT signaling pathway.

Indexed as

immune infiltrationNOX4PI3K/AKT signaling pathwayProstate adenocarcinoma (PRAD)reactive oxygen species (ROS)

Identifiers

PMID42293855
PMCPMC13263845

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.